Trial · NCT07901842
Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence
NCT07901842, Phase 3, Not yet recruiting, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence. Trials, record NCT07901842. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901842
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence
- NCT number
- NCT07901842
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 826 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Acute Ischemic Stroke
- Interventions
- Recombinant Human Prourokinase for Injection (rhPro-UK), Matching Placebo for Recombinant Human Prourokinase
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants With a Modified Rankin Scale Score of 0-1 at 90 Days | 90 ± 7 days after randomization | The proportion of participants achieving a modified Rankin Scale (mRS) score of 0 or 1. The mRS ranges from 0 (no symptoms) to 6 (death), with lower scores indicating better functional outcomes. |
| Secondary | Ordinal Distribution of Modified Rankin Scale Scores at 90 Days | 90 ± 7 days after randomization | The distribution of modified Rankin Scale (mRS) scores from 0 (no symptoms) to 6 (death), with higher scores indicating worse functional outcomes. |
| Secondary | Proportion of Participants With a Modified Rankin Scale Score of 0-2 at 90 Days | 90 ± 7 days after randomization | The proportion of participants achieving an mRS score of 0-2. The mRS ranges from 0 (no symptoms) to 6 (death). |
| Secondary | Proportion of Participants With a Modified Rankin Scale Score of 0-3 at 90 Days | 90 ± 7 days after randomization | The proportion of participants achieving an mRS score of 0-3. The mRS ranges from 0 (no symptoms) to 6 (death). |
| Secondary | Change in National Institutes of Health Stroke Scale Score From Baseline to 24 Hours | Baseline and 24 hours after randomization | Change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to 24 hours. The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological impairment. |
| Secondary | Change in National Institutes of Health Stroke Scale Score From Baseline to Day 7 | Baseline and 7 days after randomization | Change in NIHSS score from baseline to day 7. The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological impairment. |
| Secondary | Proportion of Participants With Early Neurological Improvement at 24 Hours | 24 hours after randomization | The proportion of participants whose NIHSS score decreases by at least 4 points from baseline or reaches 0-1 at 24 hours. |
| Other | Incidence of Symptomatic Intracranial Hemorrhage Within 36 Hours | Within 36 hours after randomization | The proportion of participants experiencing symptomatic intracranial hemorrhage (sICH), assessed according to ECASS III criteria. |
| Other | Incidence of Parenchymal Hematoma Within 36 Hours | Within 36 hours after randomization | The proportion of participants with parenchymal hematoma (PH), assessed according to ECASS imaging classification. |
| Other | All-Cause Mortality at 90 Days | 90 ± 7 days after randomization | The proportion of participants who die from any cause during the 90-day follow-up period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901842
GET https://conductscience.org/api/trials/v1/NCT07901842/registered